Lawmakers in the United States are urging President Joe Biden to increase scrutiny on Chinese biotech firms. The call comes as tensions between the two countries continue to escalate.
Members of Congress are pushing for more transparency and accountability from Chinese companies operating in the biotech sector. They argue that these firms may pose national security risks and could potentially steal intellectual property.
The lawmakers are specifically calling on President Biden to address the issue and take a stronger stance against Chinese biotech companies. They believe that the administration should be more vocal in calling out any potential threats posed by these firms.
This push for increased scrutiny on Chinese biotech firms is part of a broader effort to address concerns about China's growing influence in various industries, including technology and healthcare. Lawmakers are concerned about the implications of allowing Chinese companies to operate unchecked in sensitive sectors.
President Biden has yet to respond to these calls from lawmakers, but the issue is likely to remain a point of contention in US-China relations. The outcome of this debate could have significant implications for the future of biotech collaboration between the two countries.
